Last $3.12 USD
Change Today 0.00 / 0.00%
Volume 0.0
ZLIXF On Other Exchanges
Symbol
Exchange
Continuous
OTC US
Frankfurt
OTC US
As of 8:10 PM 12/31/14 All times are local (Market data is delayed by at least 15 minutes).

zeltia sa (ZLIXF) Key Developments

Zeltia SA Presents at The Trout Group 's Annual 1x1 Management Access Event, Jan-12-2015

Zeltia SA Presents at The Trout Group 's Annual 1x1 Management Access Event, Jan-12-2015 . Venue: The Handlery Hotel, 351 Geary Street, Union Square, San Francisco, California, United States.

Zeltia Reports Earnings Results for the Nine Months Ended September 2014

Zeltia reported earnings results for the nine months ended September 2014. For the period, the company's net sales grew by 7% year on year to EUR 116.9 million. Net profit amounted to EUR 17.5 million, a 24.3% increase compared with the same period in 2013. Positive performance was driven mainly by star oncology product Yondelis (trabectedin), net sales of which reached EUR 57 million, and the net sales of Biofarmacia increased by 7% to EUR 61.2 million.

Zeltia SA Presents at CF&B 14th Large & Midcap Event, Oct-02-2014

Zeltia SA Presents at CF&B 14th Large & Midcap Event, Oct-02-2014 . Venue: Palais Brongni, 28 Place de la Bourse, entrée Rue Vivienne, 75002 Paris, France.

Zeltia Announces Earnings Results for the Second Quarter and First Half Ended June 30, 2014

Zeltia announced earnings results for the second quarter and first half ended June 30, 2014. For the quarter, the company reported that loss attributable to equity-holders of the parent was €147,000, compared to a loss attributable to equity-holders of the parent of €1.41 million for the same quarter ended June 30, 2013. Total revenue was €44.92 million, compared to €41.03 million for the same quarter ended June 30, 2013. For the first half, the company reported net sales amounted to €78.2 million up 10% with respect to the same period last year. EBITDA amounted to €22.1 million in first half of 2014, a 12% increase with respect to the same period last year. The oncology area was the main contributor to this performance, accounting for €24 million against €22.5 million in first half of 2013. EBITDA increased notably despite the increase in R&D spending +9.8%, attributable mainly to the pivotal Phase III trial with Aplidin in multiple myeloma. Income attributable to equity-holders of the parent was €16.75 million, compared to €14.40 million for the same period ended June 30, 2013. Total revenue was €98.05 million, compared to €91.19 million for the same period ended June 30, 2013.

Zeltia SA to Report Q2, 2014 Results on Jul 29, 2014

Zeltia SA announced that they will report Q2, 2014 results on Jul 29, 2014

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ZLIXF:US $3.12 USD 0.00

ZLIXF Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for ZLIXF.
View Industry Companies
 

Industry Analysis

ZLIXF

Industry Average

Valuation ZLIXF Industry Range
Price/Earnings -- Not Meaningful
Price/Sales -- Not Meaningful
Price/Book -- Not Meaningful
Price/Cash Flow 39.3x
TEV/Sales 3.0x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ZELTIA SA, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.